Business
business

Nintendo’s stock popped on Switch 1 price hikes and powered-up Switch 2 sales

Since releasing its long-awaited (and much-needed) Switch 2 console back in June, Nintendo stock has been leaping like Mario — and now, its not just strong sales reports helping to boost the video game company’s star-powered share price.

Nintendo’s stock soared 7% on Monday, and rose another 1.3% in trading in Tokyo today, after the company announced that the price of the original Switch and its related products would go up in the US “based on market conditions” (read: tariffs). That leaves the stock within touching distance of an all-time high.

Indeed, the price of the Switch 1 went up to ~$339 on Sunday — after eight years of costing ~$299 — while the Switch OLED went up by $50, The Verge reported, in line with the 15% tariff on Japanese imports announced on July 31. Still, if price adjustments weren’t enough, a strong start for Switch 2 sales seems to be enough for investors to play with.

Nintendo switch 2 sales forecast
Sherwood News

Nintendo’s fiscal first-quarter results, released Friday, showed that more than 5.8 million Switch 2 consoles have sold from April to June — more than twice the pace of the original Switch, having sold 2.7 million units in its first quarter. Off the back of these figures, Nintendo has said it still expects to shift 15 million Switch 2 consoles, at $450 apiece, by the end of FY26.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services' General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

Hims launched the product last week, a seeming copy of a recently released and patented drug, and immediately drew fire from Novo Nordisk and regulators.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services' General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

Hims launched the product last week, a seeming copy of a recently released and patented drug, and immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26
2025 WWD Beauty CEO Summit - Day 2

CFO Mandy Fields sees e.l.f. Beauty in growth mode, as company beats on sales and earnings

The new owner of rhode beat estimates for its fiscal third quarter and boosted its guidance for the full year, even as headwinds in the UK and Germany continued.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.